All Trials

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: PSMA PET–positive metastatic castration‑resistant prostate cancer on continuous ADT after ≥1 ARSI; no PSMA‑negative lesions, with Part 3 requiring prior Lu‑177–PSMA (and allowing ≤1 prior taxane). Investigational therapy is Ac‑225 rosopatamab tetraxetan (225Ac‑J591), a PSMA‑targeted alpha‑emitting monoclonal antibody delivered in a single fractionated cycle (Day 1/15) at 45–60 kBq/kg, with randomized dose optimization in PSMA‑RT–naive patients and dose escalation/expansion in those post‑Lu‑177.

ClinicalTrials.gov ID: NCT06549465

A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with metastatic castration-resistant prostate cancer progressing on abiraterone (ECOG 0–1, on continuous ADT, no prior second‑generation AR inhibitor or mCRPC chemotherapy) are randomized to enzalutamide alone versus enzalutamide plus ZEN003694, an oral pan-BET bromodomain inhibitor (BRD2/3/4/BRDT) aiming to suppress AR/MYC-driven transcription. Two predefined cohorts (poor vs good prior abiraterone responders) are included; crossover from control at radiographic progression is allowed.

ClinicalTrials.gov ID: NCT04986423

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced solid tumors after ≥1 prior therapy, enriched for ARID1A-altered cancers, ATM-deficient tumors (including mCRPC), and a post–checkpoint inhibitor endometrial cancer cohort; measurable disease required. Patients receive the ATR inhibitor ceralasertib (monotherapy for BAF250a-negative ARID1A or ATM-loss, ceralasertib + PARP inhibitor olaparib for BAF250a-positive ARID1A, or ceralasertib + anti–PD-L1 durvalumab for endometrial), leveraging DNA damage response targeting and potential synergy with PARP inhibition or immunotherapy.

ClinicalTrials.gov ID: NCT03682289

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Men with metastatic castration-resistant prostate adenocarcinoma after at least one second-generation AR inhibitor (± prior taxane), castrate and ECOG 0–2, with a lesion accessible for transperineal intratumoral access/biopsy, and without visceral or brain metastases. Treatment involves partial oncolysis of a target lesion followed by intratumoral SV-102, a fixed-dose multi-agent immunotherapy (anti-CTLA-4, anti-PD-1, CD40 agonist, TLR9 agonist) designed to induce in situ vaccination; dose is escalated/optimized across cohorts.

ClinicalTrials.gov ID: NCT06533644

A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or recurrent HPV16-positive cancers (e.g., cervical, oropharyngeal, anal, vulvar, vaginal, penile) who are HLA-A*02:01–positive receive lymphodepleting cyclophosphamide/fludarabine, a single infusion of autologous T cells engineered with a high-avidity TCR targeting HPV16 E7(11–19), followed by high-dose IL-2. Designed for patients post standard therapy or who declined it; controlled brain metastases allowed.

ClinicalTrials.gov ID: NCT05686226

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Treatment-naïve adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive modified FOLFIRINOX plus nivolumab with NC410, a recombinant LAIR-2–IgG1 Fc fusion protein that binds tumor collagen to block LAIR-1 inhibitory signaling and enhance T-cell activity; a second cohort adds ipilimumab. Excludes prior ICI/PDAC therapy and significant autoimmune/immunosuppression, with efficacy and safety endpoints including ORR, PFS, and toxicity.

ClinicalTrials.gov ID: NCT06941857

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Previously untreated adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) are randomized to gemcitabine/nab-paclitaxel plus SBP-101 (ivospemin) versus placebo; SBP-101 is a polyamine analogue that modulates polyamine metabolism (inhibits ODC1 and S-adenosylmethionine decarboxylase) with preferential pancreatic uptake. Key exclusions include prior systemic therapy for metastasis, BRCA1/2 mutation if known, metformin use, retinopathy risk, active infections, and significant cardiopulmonary comorbidity.

ClinicalTrials.gov ID: NCT05254171

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with inoperable, advanced, well-differentiated (G1–2) SSTR-positive GEP-NETs that progressed after prior 177Lu-SSA PRRT (with ≥6 months disease control) are randomized to RYZ101 (225Ac-DOTATATE, an SSTR2-targeted alpha-emitting radiopharmaceutical) versus investigator’s choice of everolimus, sunitinib, octreotide, or lanreotide. Key eligibility includes Krenning 3–4 on SSTR-PET, ECOG 0–2, and adequate organ function; excludes prior non–Lu-177 PRRT, radioembolization, significant cardiovascular disease, and cirrhosis.

ClinicalTrials.gov ID: NCT05477576

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced solid tumors—specifically gastric/GEJ adenocarcinoma (post up to two lines), untreated metastatic pancreatic ductal adenocarcinoma, and previously treated biliary tract cancer—are enrolled to receive the CLDN18.2-targeted antibody–drug conjugate AZD0901 (sonesitatug vedotin, MMAE payload) as monotherapy or combined with standard pancreatic chemotherapy backbones. Suitable for ECOG 0–1 patients without prior MMAE-ADC or CLDN18.2 therapy (except mAbs) and without significant GI bleeding, ILD/pneumonitis, CNS mets, or grade ≥2 neuropathy.

ClinicalTrials.gov ID: NCT06219941